David A. Siegel Kal Vista Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 38,322 shares of KALV stock, worth $388,968. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,322

Previous 63,122 39.29%

Holding current value

$388,968

Previous $743,000 40.38%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$9.46 - $15.39 $234,608 - $381,672	-24,800 Reduced 39.29%	38,322 $443,000
Q2 2024 Aug 14, 2024	SELL	$10.35 - $12.49 $861,120 - $1.04 Million	-83,200 Reduced 56.86%	63,122 $743,000
Q1 2024 May 15, 2024	SELL	$11.07 - $16.04 $622,134 - $901,448	-56,200 Reduced 27.75%	146,322 $1.74 Million
Q4 2023 Feb 14, 2024	BUY	$7.58 - $12.25 $213,756 - $345,450	28,200 Added 16.18%	202,522 $2.48 Million
Q3 2023 Nov 14, 2023	BUY	$8.95 - $11.35 $368,739 - $467,620	41,200 Added 30.95%	174,322 $1.68 Million
Q2 2023 Aug 14, 2023	BUY	$7.73 - $10.57 $258,955 - $354,095	33,500 Added 33.63%	133,122 $1.2 Million
Q1 2023 May 15, 2023	SELL	$6.3 - $8.39 $78,750 - $104,875	-12,500 Reduced 11.15%	99,622 $783,000
Q4 2022 Feb 14, 2023	SELL	$4.2 - $14.24 $10,500 - $35,600	-2,500 Reduced 2.18%	112,122 $757,000
Q3 2022 Nov 14, 2022	SELL	$9.85 - $16.83 $88,650 - $151,469	-9,000 Reduced 7.28%	114,622 $1.66 Million
Q2 2022 Aug 15, 2022	BUY	$8.16 - $15.1 $554,064 - $1.03 Million	67,900 Added 121.85%	123,622 $1.22 Million
Q1 2022 May 16, 2022	SELL	$11.2 - $16.97 $665,280 - $1.01 Million	-59,400 Reduced 51.6%	55,722 $821,000
Q4 2021 Feb 14, 2022	SELL	$12.36 - $18.28 $65,508 - $96,884	-5,300 Reduced 4.4%	115,122 $1.52 Million
Q3 2021 Nov 15, 2021	BUY	$17.11 - $24.49 $1.74 Million - $2.5 Million	101,900 Added 550.16%	120,422 $2.1 Million
Q2 2021 Aug 16, 2021	BUY	$23.12 - $29.91 $208,080 - $269,190	9,000 Added 94.52%	18,522 $444,000
Q1 2021 May 17, 2021	BUY	$14.69 - $42.57 $139,878 - $405,351	9,522 New	9,522 $245,000
Q3 2019 Nov 14, 2019	SELL	$11.6 - $21.67 $118,575 - $221,510	-10,222 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$18.44 - $30.89 $188,493 - $315,757	10,222 New	10,222 $226,000

Others Institutions Holding KALV

# of Institutions

125

Shares Held

47.8M

Call Options Held

551K

Put Options Held

110K

View Full List

About KalVista Pharmaceuticals, Inc.

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $250M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

More about KALV

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account